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Introduction {#acn351062-sec-0001}
============

Febrile infection‐related epilepsy syndrome (FIRES) is a severe epileptic encephalopathy with new‐onset super‐refractory status epilepticus that presents with a febrile illness prior to seizure onset.[^1^](#acn351062-bib-0001){ref-type="ref"} Status epilepticus in individuals with FIRES is highly refractory, and, even though a cytokine‐mediated mechanism has been proposed, the pathophysiology remains entirely unknown.[^2^](#acn351062-bib-0002){ref-type="ref"}, [^3^](#acn351062-bib-0003){ref-type="ref"} FIRES shares many clinical features with developmental and epileptic encephalopathies (DEE). Over the last two decades, genetic studies have identified the underlying cause of many previously poorly understood epilepsy syndromes, including disease‐causing *SCN1A* variants in up to 90% of individuals with Dravet Syndrome[^4^](#acn351062-bib-0004){ref-type="ref"} and disease‐causing *KCNT1* variants in a significant fraction of individuals with epilepsy with migrating focal seizures.[^5^](#acn351062-bib-0005){ref-type="ref"} Genetic testing has become a common diagnostic modality and is routinely performed in children and adults with DEE. The diagnostic yield is considered 15--20%[^6^](#acn351062-bib-0006){ref-type="ref"}, [^7^](#acn351062-bib-0007){ref-type="ref"} and reaches up to 50% in individuals with neonatal epileptic encephalopathies,[^8^](#acn351062-bib-0008){ref-type="ref"} largely due to de novo variants in genes encoding ion channels or synaptic proteins.

Ever since its initial description in 2010,[^1^](#acn351062-bib-0001){ref-type="ref"} the cause of Febrile Infection‐Related Epilepsy Syndrome (FIRES) has been a matter of debate. Given the absence of otherwise explanatory factors, two avenues of research have been pursued to better understand the underlying disease mechanism, including (1) the identification and delineation of a potentially dysregulated immune response and (2) genetic studies in parallel to genetic investigations in other nonlesional epilepsies. While studies into the disease mechanism have recently focused on a dysregulation of the IL1 response[^9^](#acn351062-bib-0009){ref-type="ref"} with reports suggesting a promising therapeutic effect of anakinra,[^10^](#acn351062-bib-0010){ref-type="ref"}, [^11^](#acn351062-bib-0011){ref-type="ref"}, [^12^](#acn351062-bib-0012){ref-type="ref"}, [^13^](#acn351062-bib-0013){ref-type="ref"} the primary cause leading to this response is unknown.

Given the suspicion of an underlying genetic cause, multiple studies over the last decade have assessed the role of genetic factors in FIRES (detailed in [Supplementary Information](#acn351062-sup-0001){ref-type="supplementary-material"}). However, excluding individuals subsequently included in our study, we only identified less than 30 individuals with FIRES reported to have undergone sequencing for candidate genes, gene panel analysis, or whole exome sequencing in these studies. A subset of studies reported alleged genetic findings in FIRES. By current diagnostic criteria, however, none of the findings would be considered explanatory.

FIRES is extremely rare with less than 50 new cases in the United States every year. Accordingly, assembling patient cohorts is challenging. We therefore established an international study to perform exome sequencing in individuals with FIRES. We reasoned that, in parallel to DEE, autism, and other neurodevelopmental disorders, the genetic basis of FIRES can be identified through a modern next‐generation sequencing approach.

Patients and Methods {#acn351062-sec-0002}
====================

Subjects {#acn351062-sec-0003}
--------

We included a cohort of 50 individuals with FIRES from centers in Kiel, Germany (n = 30), Paris, France (n = 9), Israel (n = 7), Italy (n = 2), and the US (n = 2) for the current study. The diagnosis of FIRES was confirmed by two senior physicians (A.v.B., R.N.) based on consensus criteria,[^14^](#acn351062-bib-0014){ref-type="ref"} and standardized phenotyping was obtained for all individuals. The study was approved by the Institutional Review Board of the University of Kiel, Germany, Hôpital Necker‐Enfants Malades, Paris, France, and Children's Hospital of Philadelphia.

Exome sequencing and HLA sequencing {#acn351062-sec-0004}
-----------------------------------

Exome sequencing was performed for patient--parent trios and singletons at four sites. Of these, 18 individuals were sequenced at Broad institute with Nextera Rapid Capture Exome kit through the Epi25 Project, 13 individuals at Cologne Center for Genomics with Agilent Technologies SureSelect V6 R2 kit, 11 individuals at Institut Imagine, Paris with Agilent Technologies 50 V5 kit, and 6 individuals with Truseq Exome Enrichment kit at the Institute of Clinical Molecular Biology (ICMB), Kiel. Molecular HLA typing was performed at ICMB using a targeted NGS method as previously reported.[^15^](#acn351062-bib-0015){ref-type="ref"}

Bioinformatic analysis for exome and HLA sequencing {#acn351062-sec-0005}
---------------------------------------------------

Exome data were analyzed through a bioinformatic pipeline as previously described.[^16^](#acn351062-bib-0016){ref-type="ref"}, [^17^](#acn351062-bib-0017){ref-type="ref"} Analysis for pathogenic variants in genetic etiologies for human epilepsies was performed according to criteria of the American College of Medical Genetics and Genomics (ACMG).[^18^](#acn351062-bib-0018){ref-type="ref"} HLA imputation was performed using HLAscan, including 29 cases and 529 controls of European ancestry. Using PyHLA, significant HLA associations were tested under an additive allelic model,[^19^](#acn351062-bib-0019){ref-type="ref"} correcting for multiple testing using the Benjamini‐Hochberg FDR method.

Selection of FIRES candidate genes {#acn351062-sec-0006}
----------------------------------

In trio whole‐exome data, we selected (a) de novo, X‐linked, and bi‐allelic variants absent in population databases. For both trio and singleton exome data, we further identified (b) ClinVar pathogenic variants,[^20^](#acn351062-bib-0020){ref-type="ref"} (c) nonpopulation variants in 101 epilepsy‐related genes, (d) Protein Truncating Variants (PTV) in genes resistant to loss‐of‐function variation (pLI score \> 0.95),[^21^](#acn351062-bib-0021){ref-type="ref"} and (e) deleterious missense variants (CADD score \> 20) within constrained coding regions (CCR \> 95th percentile).[^22^](#acn351062-bib-0022){ref-type="ref"} The selection strategy for these candidate genes is further outlined in the [Supplementary Information](#acn351062-sup-0001){ref-type="supplementary-material"}.

Results {#acn351062-sec-0007}
=======

Spectrum of clinical features {#acn351062-sec-0008}
-----------------------------

Our cohort included 17 females and 33 males (clinical features are shown in Table [S1](#acn351062-sup-0001){ref-type="supplementary-material"}). In brief, three individuals (F3, F44, and F51) had prior febrile seizures, but none of the individuals had epilepsy diagnosed prior to the onset of FIRES. Median age of onset of the acute phase was 6 years (range 2--15 years). EEGs performed in the acute phase showed epileptiform activity in 41/50, mostly multifocal discharges arising bilaterally from the frontal and temporal regions. Developmental outcome was documented in 49/50 individuals, including 11/49 with mild, 18/49 with moderate, and 13/49 with severe intellectual disability. Seven individuals had resolution of FIRES without intellectual deficits. 44/47 individuals with documented development prior to seizure onset did not have developmental concerns, the remaining three individuals had anxiety and obsessive‐compulsive disorder (F11), attention deficit hyperactivity disorder (ADHD, F14), and language delay (F43).

Exome sequencing {#acn351062-sec-0009}
----------------

### Known genetic etiologies in human epilepsies {#acn351062-sec-0010}

None of the 50 individuals had pathogenic or likely pathogenic variants in known genetic etiologies for human epilepsies. The 27 patient--parent trios were further analyzed for de novo, X‐linked, and bi‐allelic variants absent in population databases (Table [1](#acn351062-tbl-0001){ref-type="table"}). No gene was found to be affected by a de novo variant or bi‐allelic variants in two or more individuals. The only known variant in a gene related to human epilepsies was a previously reported de novo c.G1117A (p.E373K) variant in *DNM1* in F26.[^23^](#acn351062-bib-0023){ref-type="ref"} However, as this variant in *DNM1* occurred outside the typical mutation cluster and the presentation was incompatible with the typical phenotype, it remained of uncertain significance. We next analyzed a virtual panel of 101 curated epilepsy‐related genes that are typically analyzed in a diagnostic context (Table [S2](#acn351062-sup-0001){ref-type="supplementary-material"}). This analysis identified a total of seven variants absent in population databases, including two variants in *KCNQ3* (F38 and F28) and one variant in *SCN2A* (F29). The *KCNQ3* variant in F38 was paternally inherited and parental testing was not available for F28. Both these *KCNQ3* variants occurred in the C‐terminal end, where population variants in this gene are common and hence, a profound effect on protein function is unlikely. The variant c.A2851G (p.M951V) in *SCN2A* occurred close to the selectivity filter, paralogous to *SCN1A* variants observed in Dravet Syndrome.[^24^](#acn351062-bib-0024){ref-type="ref"} However, the variant in F29 was inherited from an unaffected father and is not considered explanatory for the individual's epilepsy. All other nonpopulation variants in epilepsy genes occurred in genes incompatible with the FIRES phenotype. The analysis of ClinVar pathogenic variants identified a reported pathogenic variant in *FOXP2* (p.Q175delinsQQQQQ) in F47, a known genetic etiology for speech disorders. As this variant was inherited from an unaffected father, we consider it noncontributory to the FIRES phenotype.

###### 

Candidate variants in FIRES.

  ID                                                                      Test     Inheritance                                         Gene         Variant (c./p.)                                Protein name                                               Transcripts
  ----------------------------------------------------------------------- -------- --------------------------------------------------- ------------ ---------------------------------------------- ---------------------------------------------------------- ----------------
  Variants with monogenic inheritance                                                                                                                                                                                                                         
  F17                                                                     Trio     de novo                                             *NPY2R*      c.A52G;p.K18E                                  Neuropeptide y receptor y2                                 NM_000910.3
  F23                                                                     Trio     de novo                                             *MYO1D*      c.A1348G;p.K450E                               Myosin ID                                                  NM_001303279.1
  F23                                                                     Trio     de novo                                             *UNC50*      c.582dupA;p.G194fs                             Unc‐50 Inner nuclear membrane RNA binding protein          NM_001330353.1
  F23                                                                     Trio     de novo                                             *SPICE1*     c.G1540C;p.D514H                               Spindle‐ and centriole‐associated protein 1                NM_001331078.1
  F32                                                                     Trio     de novo                                             *NAV1*       c.G982A;p.G328S                                Neuron navigator 1                                         NM_020443.4
  F7                                                                      Trio     de novo                                             *LRIF1*      c.C1585T;p.Q529X                               Ligand‐dependent nuclear receptor‐interacting factor 1     NM_018372.3
  F8                                                                      Trio     Compound                                            *UNC79*      c.G4087T;p.V1363L c.C4654A;p.L1552I            Unc79 homolog, NALCN channel complex subunit               NM_001346218.1
  F29                                                                     Trio     de novo                                             *KDM2B*      c.G3172A;p.V1058I                              Lysine‐specific demethylase 2b                             NM_001005366.1
  F32                                                                     Trio     Compound                                            *KIAA0586*   c.137delG;p.R46fs c.1793_1794del; p.E598fs     KIAA0586 protein                                           NM_001244191.1
  F26                                                                     Single   de novo[^1^](#acn351062-note-0006){ref-type="fn"}   *DNM1*       c.G1117A;p.E373K                               Dynamin 1                                                  NM_004408.2
  ClinVar pathogenic variants for neurological disorders                                                                                                                                                                                                      
  F27                                                                     Single   Unknown                                             *SPG7*       c.C1369T;p.R457X                               Paraplegin (Hereditary spastic paraplegia)                 NM_003119.3
  F47                                                                     Trio     Paternal                                            *FOXP2*      c.525_526insCAGCAG CAACAA; p.Q175delinsQQQQQ   Forkhead box protein p2 (Speech‐language disorder‐1)       NM_148900.3
  F17                                                                     Trio     Maternal                                            *POLG*       c.G1399A;p.A467T                               DNA Polymerase Gamma, Catalytic Subunit (Leigh Syndrome)   NM_001126131.1
  F30                                                                     Trio     Paternal                                            *CAPN3*      c.549delA;p.P183fs                             Calpain 3 (Limb‐girdle muscular dystrophy)                 NM_000070.2
  Variants in genetic etiologies for epilepsy absent in gnomAD database                                                                                                                                                                                       
  F35                                                                     Single   Unknown                                             *GNAO1*      c.A425C;p.N142T                                G Protein Subunit Alpha O1                                 NM_020988.2
  F38                                                                     Single   Homozygous                                          *LGI1*       c.A615T;p.E205D                                Leucine‐rich gene, glioma‐inactivated, 1                   NM_001308275.1
  F38                                                                     Single   Paternal                                            *KCNQ3*      c.G1898A;p.G633E                               Potassium Voltage‐Gated Channel Subfamily Q Member 3       NM_004519.3
  F38                                                                     Single   Unknown                                             *ARX*        c.G503A;p.S168N                                Aristaless‐related homeobox                                NM_139058.2
  F27                                                                     Single   Unknown                                             *ALG13*      c.C905T;p.A302V                                UDP‐N‐Acetylglucosaminyl‐transferase                       NM_001257230.1
  F28                                                                     Single   Unknown                                             *KCNQ3*      c.G1854A;p.M618I                               Potassium Voltage‐Gated Channel Subfamily Q Member 3       NM_004519.3
  F29                                                                     Trio     Paternal                                            *SCN2A*      c.A2851G;p.M951V                               Sodium channel, voltage‐gated, type ii, alpha subunit      NM_001040143.1

Previously published as de novo[^23^](#acn351062-bib-0023){ref-type="ref"}.
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### Candidate variants and Copy Number Variation (CNV) analysis {#acn351062-sec-0011}

We identified de novo variants absent in population databases in *NPY2R*, *MYO1D*, *UNC50*, *SPICE1*, *NAV1*, and *LRIF1*. None of these genetic etiologies are established in neurodevelopmental disorders or epilepsy, but occur in brain‐expressed genes intolerant to mutation, including genes implicated in brain development (*NPY2R*, *UNC50*, *NAV1,* [Supplementary Information](#acn351062-sup-0001){ref-type="supplementary-material"}). We further assessed potential candidate variants by identifying protein‐truncating variants in genes resistant to loss‐of‐function variation and missense variants in genomic regions devoid of variation. We identified a total of seven protein truncating variants and 10 missense variants (Table [2](#acn351062-tbl-0002){ref-type="table"}). None of the implicated genes are established causes for neurological disease. Analysis of copy number variations from exome sequences did not identify pathogenic deletions or duplications ([Supplementary Information](#acn351062-sup-0001){ref-type="supplementary-material"}).

###### 

Qualifying protein‐truncating variants and missense variants in FIRES.

  ID                                                                                               Test     Inheritance   Gene          Variant (c./p.)            Protein name                                                                                   Transcripts
  ------------------------------------------------------------------------------------------------ -------- ------------- ------------- -------------------------- ---------------------------------------------------------------------------------------------- ----------------
  Protein‐truncating variants (PTV) with pLI \> 0.95                                                                                                                                                                                                              
  F41                                                                                              Single   Unknown       *TBX1*        c.1065_1066del; p.P355fs   T‐Box Transcription Factor 1                                                                   NM_080646.1
  F33                                                                                              Single   Unknown       *GNAS*        c.G29A;p.W10X              Guanine Nucleotide Binding Protein, Alpha Stimulating Activity Polypeptide 1                   NM_016592.3
  F34                                                                                              Single   Unknown       *WWP2*        c.G403T;p.G135X            NEDD4‐Like E3 Ubiquitin‐Protein Ligase WWP2                                                    NM_001270454.1
  F51                                                                                              Trio     Paternal      *JAKMIP1*     c.G2053T;p.E685X           Janus Kinase and Microtubule Interacting Protein 1                                             NM_001099433.1
  F1                                                                                               Trio     Maternal      *HSP90AB1*    c.2172_2176del; p.D724fs   Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 1                                   NM_001271969.1
  F30                                                                                              Trio     Maternal      *BRD1*        c.1412delA; p.D471fs       Bromodomain‐containing protein 1                                                               NM_001349940.1
  F30                                                                                              Trio     Maternal      *ITGB8*       c.C208T;p.Q70X             Integrin, beta‐8                                                                               NM_002214.2
  Missense with phred‐scaled CADD score \> 20 and conserved coding region (CCR) percentile \> 90                                                                                                                                                                  
  F35                                                                                              Single   Unknown       *ABCB6*       c.A2175C;p.K725N           Phosphatidylinositol glycan anchor biosynthesis class X protein                                NM_001349828.1
  F35                                                                                              Single   Unknown       *MGAT4D*      c.T919A;p.F307I            Mannosyl (Alpha‐1,3‐)‐Glycoprotein Beta‐1,4‐N‐Acetylglucosaminyltransferase Family, Member D   NM_001277353.1
  F38                                                                                              Single   Unknown       *DIP2C*       c.C3183G;p.H1061Q          Disco‐interacting protein 2 homolog C                                                          NM_014974.2
  F22                                                                                              Single   Unknown       *NDUFAB1*     c.A1C;p.M1L                NADH‐ubiquinone oxidoreductase 1 alpha/beta subcomplex, 1                                      NM_005003.2
  F27                                                                                              Single   Unknown       *BCAS4*       c.G619A;p.A207T            Breast carcinoma amplified sequence 4                                                          NM_017843.4
  F46                                                                                              Single   Unknown       *RC3H2*       c.G3164C;p.R1055T          Ring finger and CCCH‐type zinc finger domains‐containing protein 2                             NM_001100588.1
  F31                                                                                              Trio     Maternal      *CDKN2AIP*    c.C1708T;p.P570S           Cyclin‐dependent kinase inhibitor 2A‐interacting protein                                       NM_017632.3
  F48                                                                                              Trio     Maternal      *HIST2H2AB*   c.C222G;p.N74K             Histone gene cluster 2, H2A histone family, Member B                                           NM_175065.2
  F7                                                                                               Trio     Paternal      *GHRH*        c.A164C;p.Q55P             Growth hormone‐releasing hormone                                                               NM_001184731.2
  F42                                                                                              Single   Unknown       *SLC25A1*     c.526 + 1G\>A              Solute Carrier Family 25 (Mitochondrial Carrier; Citrate Transporter), Member 1                NM_005984.4
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HLA sequencing {#acn351062-sec-0012}
--------------

We performed HLA sequencing in 29 individuals and compared allelic associations with 529 population controls. We did not identify a prominent HLA allele but found tentative associations with HLA‐C\*07:01 \[OR 8.7, 95% CI 3.55--21.30\], HLA‐A\*02:05 \[OR 12.99, 95% CI 3.56--47.39\], and HLA\*A: 03:01 \[OR 0.1, 95% CI 0.01--0.77\]. Given the lack of a consistent HLA signature, we consider these results inconclusive. None of the identified HLA associations have previously been reported in other disorders.

Discussion {#acn351062-sec-0013}
==========

In our study, we aimed to identify the genetic basis of FIRES using whole exome sequencing, reasoning that the clinical features are related to developmental and epileptic encephalopathies (DEE) where genetic causes are routinely identified. None of the individuals with FIRES had explanatory variants in known genetic etiologies for epilepsies or neurodevelopmental disorders. Even though we identified several variants of uncertain significance in known epilepsy‐related genes and potential candidate genes, none of the identified variants were considered disease‐causing.

In our study, we do not observe the same rate of pathogenic variants in established epilepsy genes that we would expect in an equally‐sized cohort of individuals with DEE, such as Infantile Spasms or Lennox‐Gastaut Syndrome where the diagnostic rate is 15% or higher. Assuming a comparable diagnostic rate for FIRES, we would have expected at least three individuals with pathogenic variants, allowing for the conclusion that the rate of pathogenic or likely pathogenic variants in known epilepsy genes in FIRES is low (95% CI 0--0.09 for variant frequency in 0/50 individuals; *P* = 0.006 for null probability of 0.15, see [Supplementary Information](#acn351062-sup-0001){ref-type="supplementary-material"}). Status epilepticus in FIRES is preceded by a mild febrile illness,[^14^](#acn351062-bib-0014){ref-type="ref"}, [^25^](#acn351062-bib-0025){ref-type="ref"} suggesting a possible immune or inflammatory mechanism. None of the candidate genes identified in our study are implicated in human immunological disorders, and HLA sequencing failed to identify a strong disease association. Tentative associations with HLA‐C\*07:01, HLA‐A\*02:05, and HLA‐A\*03:01 were nonexplanatory. We cannot exclude that inherited variants, including the rare variants identified in our analysis, may contribute to the risk of FIRES. However, given the low frequency of FIRES and the small sample size, we are currently unable to make a definite statement about the role of both rare and common genetic variants in the etiology of FIRES.

Our study highlights that known genetic causes for epilepsy are not common in FIRES, which may be important in a diagnostic setting. Even though individuals with FIRES will continue to undergo a genetic work‐up, our data does not provide a rationale for prioritizing genetic studies over other diagnostic modalities. Likewise, our data advocates against withholding specific anti‐seizure medications based on genetic considerations, including a reluctance to use sodium channel blockers or valproic acid due to concerns for an underlying sodium channelopathy or *POLG*‐related disorder. Examining non‐genetic contributors or genetic mechanisms not covered by exome sequencing will be critical for future research, including the analysis of repeat expansions or non‐coding regions that are increasingly recognized in neurological disorders.

FIRES Genetics Study Group {#acn351062-sec-0014}
==========================
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